Hoth Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 6
- Market Cap
- $5M
- Introduction
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema....
Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment
Hoth Therapeutics secures U.S. patent for HT-ALZ, an Alzheimer’s treatment targeting neuroinflammation via the Substance P/Neurokinin-1 Receptor pathway. Preclinical data shows reduced neuroinflammation and improved cognitive functions, paving the way for human clinical trials.
Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ
Hoth Therapeutics' HT-ALZ shows reduced astrocyte activity in Alzheimer's mice, linked to improved cognitive function.
© Copyright 2024. All Rights Reserved by MedPath